New York, USA – May 20, 2026
Enhanced Group, Inc. announced a major update from its Institutional Review Board (IRB)-approved clinical study evaluating medically supervised performance-enhancing protocols in elite athletes, marking one of the first large-scale studies of its kind in competitive sports. The company revealed that the interventional phase of the clinical trial, known as ASCEND001, has concluded successfully, with athletes reportedly remaining healthy and medically monitored throughout the program. Enhanced also confirmed that the trial has now been officially posted on ClinicalTrials.gov for public review as the company prepares for the inaugural Enhanced Games in Las Vegas.
The study is part of the company’s broader Enhanced Medical Program, which explores the use of FDA-approved substances under individualized physician supervision combined with ongoing medical screenings and long-term health monitoring. Company executives stated that the research aims to evaluate the safety, tolerability, recovery effects, and physiological outcomes associated with medically supervised enhancement protocols in elite athletic environments. The observational follow-up phase of the trial will continue for up to five years to monitor long-term health outcomes among participants.
Enhanced Releases Aggregate Athlete Protocol Data
Ahead of the upcoming Enhanced Games competition, the company disclosed preliminary aggregate substance usage data collected during the 12-week interventional study period. According to Enhanced, 36 of the 42 participating athletes enrolled in the clinical study, while several athletes chose to compete naturally without participation in enhancement protocols.
The company reported that approximately 91% of participating athletes used testosterone or testosterone esters, while 79% used human growth hormone (hGH) under physician supervision. Additional substances included stimulants, metabolic modulators, erythropoietin (EPO), anabolic steroid agents, and hormonal support therapies. Enhanced emphasized that all substances included in the study were FDA-approved and obtained through regulated pharmaceutical supply chains, with no Category 2 banned peptides included in the research protocols.
Advertisement
Enhanced executives stated that the company is encouraged by the early findings, particularly regarding athlete recovery, injury prevention, and tolerability outcomes. Independent medical reviewers involved with the study reported that participating athletes generally maintained favorable health profiles throughout the monitored period.
Clinical Trial Explores Performance Medicine and Athlete Safety
The primary objective of the ASCEND001 trial is to assess the safety and tolerability of medically supervised enhancement compounds administered over treatment periods extending up to 25 weeks. Primary study endpoints include treatment-related adverse events and discontinuation rates, while secondary endpoints evaluate physiological performance metrics and health-related biomarkers.
Enhanced stated that all participants provided full informed consent and retained the ability to discontinue participation at any time during the study. Clinical oversight included independent monitoring mechanisms such as a Data and Safety Monitoring Board and external scientific commissions. The company emphasized that the research framework was designed to prioritize athlete safety and transparency while exploring the broader emerging field of performance medicine.
Industry observers note that the study represents a controversial but potentially influential development in sports medicine, human performance research, and personalized health optimization. The company plans to integrate insights from the clinical program into its future consumer-focused platform, known as Live Enhanced, which aims to develop individualized health and performance protocols informed by elite athlete research data.
Enhanced Games Pushes New Debate Around Sports Innovation
The inaugural Enhanced Games are scheduled to take place on May 24, 2026, in Las Vegas and are expected to attract global media attention. Organizers describe the event as a science-driven sports competition designed to explore medically supervised human performance enhancement while maintaining athlete monitoring and clinical oversight.
The announcement has generated significant discussion across sports medicine, bioethics, anti-doping policy, and performance science communities. Supporters argue that medically supervised enhancement research could improve athlete safety compared with unregulated substance use, while critics continue raising concerns regarding fairness, ethics, and long-term health risks associated with performance-enhancing compounds.
Enhanced stated that its broader mission involves creating a new category of performance medicine, combining personalized protocols, consumer health products, recovery optimization, and long-term wellness strategies. The company believes the data generated through its clinical programs may contribute to future developments in precision health, recovery science, and individualized medical optimization technologies.
Source: Enhanced press release
